Cargando…

Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model

PURPOSE: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. The β-emitting radiopharmaceutical meta-(131)I-iodo-benzylguanidine ((1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohshima, Yasuhiro, Sudo, Hitomi, Watanabe, Shigeki, Nagatsu, Kotaro, Tsuji, Atsushi B., Sakashita, Tetsuya, Ito, Yoichi M., Yoshinaga, Keiichiro, Higashi, Tatsuya, Ishioka, Noriko S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915519/ https://www.ncbi.nlm.nih.gov/pubmed/29350258 http://dx.doi.org/10.1007/s00259-017-3919-6

Ejemplares similares

Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-(211)At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
por: Ohshima, Yasuhiro, et al.
Publicado: (2019)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
por: Sudo, Hitomi, et al.
Publicado: (2019)

Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)

Enhancing the Therapeutic Effect of 2-(211)At-astato-α-methyl-L-phenylalanine with Probenecid Loading
por: Hanaoka, Hirofumi, et al.
Publicado: (2021)

Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
por: Cunningham, S. H., et al.
Publicado: (1998)

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021)

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
por: Vaidyanathan, G., et al.
Publicado: (1997)

Protection from contamination by (211)At, an enigmatic but promising alpha-particle-emitting radionuclide
por: Ohnuki, Kazunobu, et al.
Publicado: (2022)

In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([(189, 191)Pt]cisplatin) Emitting Auger Electrons
por: Obata, Honoka, et al.
Publicado: (2021)

Cardiac Iodine-123-Meta-Iodo-Benzylguanidine Uptake in Carotid Sinus Hypersensitivity
por: Tan, Maw Pin, et al.
Publicado: (2015)

Hybrid Molecules of Benzylguanidine and the Alkylating Group of Melphalan: Synthesis and Effects on Neuroblastoma Cells
por: Bruchelt, Gernot, et al.
Publicado: (2023)

Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates
por: Teze, David, et al.
Publicado: (2017)

Astatine-211 based radionuclide therapy: Current clinical trial landscape
por: Albertsson, Per, et al.
Publicado: (2023)

Internal microdosimetry of alpha-emitting radionuclides
por: Hofmann, Werner, et al.
Publicado: (2019)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

SAT-211 Is Doxazosin the Right Choice for Preoperative Management of Pheochromocytoma in Pregnancy?
por: Bustos, Mario, et al.
Publicado: (2020)

Bioaccumulation of gamma emitting radionuclides in Polysiphonia fucoides
por: Zalewska, Tamara
Publicado: (2013)

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2021)

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
por: Li, Huizi Keiko, et al.
Publicado: (2018)

Regulation of the differentiation of PC12 pheochromocytoma cells.
por: Fujita, K, et al.
Publicado: (1989)

Novel Auger-Electron-Emitting (191)Pt-Labeled Pyrrole–Imidazole Polyamide Targeting MYCN Increases Cytotoxicity and Cytosolic dsDNA Granules in MYCN-Amplified Neuroblastoma
por: Obata, Honoka, et al.
Publicado: (2023)

A Review of the Occurrence of Alpha-Emitting Radionuclides in Wild Mushrooms
por: Strumińska-Parulska, Dagmara, et al.
Publicado: (2020)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with (211)At Using Implanted Mouse Tumor
por: Yonekura, Yoshiharu, et al.
Publicado: (2022)

Pheochromocytoma (PC12) Cell Response on Mechanobactericidal Titanium Surfaces
por: Wandiyanto, Jason V., et al.
Publicado: (2018)

Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy
por: Sakashita, Tetsuya, et al.
Publicado: (2021)

Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
por: Hauck, M. L., et al.
Publicado: (1998)

Locoregional therapy with α‐emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2‐positive gastric cancer in mice
por: Li, Huizi Keiko, et al.
Publicado: (2017)

SAT-LB080 Peptide Receptor Radionuclide Therapy in Metastatic Pheochromocytoma and Paraganglioma: The Putrajaya Experience
por: Wong, Hui, et al.
Publicado: (2019)

Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis
por: Su, Dan, et al.
Publicado: (2023)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models
por: Ullrich, Martin, et al.
Publicado: (2023)

Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice
por: Obata, Honoka, et al.
Publicado: (2022)

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3
por: Takakusagi, Yoichi, et al.
Publicado: (2021)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)
por: Kuin, A, et al.
Publicado: (1999)

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
por: Aurlien, E, et al.
Publicado: (2000)

FRI211 Recurrent Hypertensive Crises In A Patient With A Large Pheochromocytoma; A Complicated Intensive Care Unit Course
por: Sokoloff, Samantha, et al.
Publicado: (2023)

Percutaneous Sclerotherapy of Renal Cysts with a Beta-Emitting Radionuclide, Holmium-166-chitosan Complex
por: Kim, Joo Hee, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_7mocq44diks4lndqt90c7fqq8t